16 December 2015 - NICE has published final guidance today which does not recommend apremilast (Otezla, Celgene) for adults with active psoriatic arthritis that has either not responded to disease-modifying antirheumatic drug (DMARD) therapy, or where such therapy is not tolerated.

For more details, go to: http://www.nice.org.uk/news/press-and-media/nice-issues-guidance-not-recommending-apremilast-for-psoriatic-arthritis